Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Change in Receivables: 2021-2025

Historic Change in Receivables for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to -$122,160.

  • InMed Pharmaceuticals' Change in Receivables fell 80.65% to -$122,160 in Q3 2025 from the same period last year, while for Sep 2025 it was $60,154, marking a year-over-year decrease of 49.60%. This contributed to the annual value of $114,690 for FY2025, which is 24.07% up from last year.
  • InMed Pharmaceuticals' Change in Receivables amounted to -$122,160 in Q3 2025, which was down 222.51% from $99,715 recorded in Q2 2025.
  • InMed Pharmaceuticals' 5-year Change in Receivables high stood at $207,019 for Q4 2023, and its period low was -$165,188 during Q1 2024.
  • Over the past 3 years, InMed Pharmaceuticals' median Change in Receivables value was $88,652 (recorded in 2023), while the average stood at $25,946.
  • The largest annual percentage gain for InMed Pharmaceuticals' Change in Receivables in the last 5 years was 14,451.57% (2022), contrasted with its biggest fall of 2,592.58% (2022).
  • InMed Pharmaceuticals' Change in Receivables (Quarterly) stood at -$638 in 2021, then spiked by 14,451.57% to $91,563 in 2022, then surged by 126.09% to $207,019 in 2023, then slumped by 110.94% to -$22,645 in 2024, then slumped by 80.65% to -$122,160 in 2025.
  • Its Change in Receivables stands at -$122,160 for Q3 2025, versus $99,715 for Q2 2025 and $105,244 for Q1 2025.